| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Chemistry, Vol 41, 571-574, Copyright © 1995 by American Association for Clinical Chemistry
MI Gerrits, JH Thijssen and HJ van Rijn
Department of Clinical Chemistry, University Hospital Utrecht, The Netherlands.
Urinary excretion of the pyridinium crosslinks pyridinoline (Pyr) and deoxypyridinoline (Dpyr) is used as a biochemical marker of bone resorption. The present study was undertaken to determine the long-term stability of these compounds in stored urine, using the HPLC method. Systematic investigation of their chemical stability in urine demonstrated that both the free and conjugated forms of Pyr and Dpyr are extremely stable: No significant changes were observed after 6 weeks at -20 degrees C storage (e.g., free Pyr 9.6 +/- 1.2 mumol/mol creatinine (before) and 10.6 +/- 3.2 (after); free Dpyr 2.3 +/- 0.2 mumol/mol creatinine (before) and 2.5 +/- 1.2 (after)). These results predict stability of urines stored for 10-20 years at -20 degrees C in the dark. Also, freezing and thawing as many as 10 times had no effect on the concentrations of the crosslinks. Study of the stability of the excretion pattern in healthy women showed substantially higher variations in excretions of free and total Dpyr (18% and 13%, respectively) than of Pyr (10% for both forms).
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  B. Westhoff, R. Krauspe, A. E. Kalke, D. Hermsen, B. Kowall, R. Willers, and U. Schneider Urinary excretion of deoxypyridinoline in Perthes' disease: A PROSPECTIVE, CONTROLLED COMPARATIVE STUDY IN 83 CHILDREN J Bone Joint Surg Br, July 1, 2006; 88-B(7): 967 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. W. Vesper, L. M. Demers, R. Eastell, P. Garnero, M. Kleerekoper, S. P. Robins, A. K. Srivastava, G. R. Warnick, N. B. Watts, and G. L. Myers Assessment and Recommendations on Factors Contributing to Preanalytical Variability of Urinary Pyridinoline and Deoxypyridinoline Clin. Chem., February 1, 2002; 48(2): 220 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Seibel, M. Lang, and W.-J. Geilenkeuser Interlaboratory Variation of Biochemical Markers of Bone Turnover Clin. Chem., August 1, 2001; 47(8): 1443 - 1450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lomeo and A. Bolner Stability of Several Biochemical Markers of Bone Metabolism Clin. Chem., August 1, 2000; 46(8): 1200 - 1202. [Full Text] [PDF]
|
|
|
|
|
|
A. Rubinacci, R. Melzi, M. Zampino, A. Soldarini, and I. Villa Total and Free Deoxypyridinoline after Acute Osteoclast Activity Inhibition Clin. Chem., September 1, 1999; 45(9): 1510 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Smith, J. L. Nillen, A. LeBlanc, A. Lipton, L. M. Demers, H. W. Lane, and C. S. Leach Collagen Cross-Link Excretion during Space Flight and Bed Rest J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3584 - 3591. [Abstract] [Full Text]
|
|
|
|
|
|
T. G. Rosano, R. T. Peaston, H. G. Bone, H. W. Woitge, R. M. Francis, and M. J. Seibel Urinary free deoxypyridinoline by chemiluminescence immunoassay: analytical and clinical evaluation Clin. Chem., October 1, 1998; 44(10): 2126 - 2132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. F Lems, J. W G Jacobs, J. W J Bijlsma, G. J M van Veen, H. H M L Houben, H. C M Haanen, M. I Gerrits, and H. J M van Rijn Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis? Ann Rheum Dis, June 1, 1997; 56(6): 357 - 363. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
